Novel Antiarrhythmic Compounds with Combined Class IB and Class III Mode of Action

E-ISSN： 1875-533x|11|1|61-69

ISSN： 0929-8673

Source： Current Medicinal Chemistry, Vol.11, Iss.1, 2004-01, pp. : 61-69

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Inhibitory effect of the class III antiarrhythmic drug nifekalant on HERG channels: mode of action

By Kushida S. Ogura T. Komuro I. Nakaya H.

European Journal of Pharmacology, Vol. 457, Iss. 1, 2002-12 ,pp. : 19-27

Elsevier

Access to resources Recommend Favorite

A Benefit-Risk Assessment of Class III Antiarrhythmic Agents

By Brendorp B.

Drug Safety, Vol. 25, Iss. 12, 2002-01 ,pp. : 847-865

Adis International

Access to resources Recommend Favorite

A benefit–risk assessment of class III antiarrhythmic agents

By Elming Hanne Brendorp Bente Pehrson Steen Pedersen Ole Dyg Køber Lars Torp-Petersen Christian

Expert Opinion on Drug Safety, Vol. 3, Iss. 6, 2004-11 ,pp. : 559-577

Informa Healthcare

Access to resources Recommend Favorite

Effects of sematilide, a novel class III antiarrhythmic agent, on membrane currents in rabbit atrial myocytes

By Ishii Y. Muraki K. Kurihara A. Imaizumi Y. Watanabe M.

European Journal of Pharmacology, Vol. 331, Iss. 2, 1997-07 ,pp. : 295-302

Elsevier

Access to resources Recommend Favorite

EGIS-7229, the new combined class III antiarrhythmic agent Lack of EAD inducing effect - rationale, design, and methods (the SWORD trial)

By Banyasz T. Magyar J. Varro A. Kovacs A. Gyonos I. Szenasi G. Nanasi P.P.

General Pharmacology, Vol. 32, Iss. 3, 1999-03 ,pp. : 329-333

Elsevier

Access to resources Recommend Favorite